×
Dual TGF-β and AURKA targeting enhances chemosensitivity in triple-negative breast cancer.
https://meetinglibrary.asco.org/record/188656
Fahad Ahmed Faruqi, MD, MPH

May 28th, 2020 - Background: Chemotherapy resistance remains a significant barrier in the effective treatment of patients with triple negative breast cancer (TNBC). TGF-β signaling is a well characterized oncogenic pathway in TNBC that promotes chemoresistance by inducing epithelial to mesenchymal transition (EMT) and tumor stemness. Aurora-A kinase (AURKA) is a serine/threonine kinase responsible for chromosom...

Effect of ARID1a oncogenic loss of function mutations on overall survival in metastatic breast cancer patients.
https://meetinglibrary.asco.org/record/189066
Veronica Mariotti, MD

May 28th, 2020 - Background: ARID1a (AT Rich Interactive Domain 1A) is part of the SWI/SNF complex, which regulates gene transcription. Its inactivation has been shown to determine resistance to endocrine therapy via enrichment of basal-like gene expression features [Xu G., 2020]. We recently reported that ARID1a lower gene expression might be associated with worse overall survival (OS) [Mariotti V., 2019]. The...

Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs).
https://meetinglibrary.asco.org/record/188612
Elias Eteshola, PhD (c)

May 28th, 2020 - Background: Breast cancers remain the most lethal malignancies amongst women worldwide and the second leading cause of cancer-related mortalities in the US. Subtype heterogeneity and aggressive invasive potential are believed to be the major contributors of these outcomes. Triple-negative breast cancer (TNBC) are notoriously aggressive, difficult-to-treat, and metastatic. Inflammation-driven tu...

Assessment of PD-L1 expression in circulating tumor cells in patients with breast cancer.
https://meetinglibrary.asco.org/record/188494
Junqing Chen

May 28th, 2020 - Background: Evidence is accumulating that the immune checkpoint blockade targeting the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free and overall survival of advanced breast cancer patients. PD-L1 tumor expression is emerging as a potential biomarker in PD-1/PD-L1 checkpoint blockade therapies. However, PD-L1 expression on tumor tissue is ...

Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
https://meetinglibrary.asco.org/record/188647
Anja Kovac, MD

May 28th, 2020 - Background: Palbociclib and other selective cyclin-dependent kinases 4 and 6 inhibitors in combination with endocrine therapy (ET) have become the standard of care in the treatment of patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC). Their role in the first and second line of therapy is well established, whereas their use in subsequent lines and after tr...

A prospective, open-label, multicenter, phase IV clinical study on the safety and efficacy of lobaplatin in the treatment of metastatic breast cancer.
https://meetinglibrary.asco.org/record/188746
Binghe Xu, MD, PhD

May 28th, 2020 - Background: Platinum-based chemotherapy is an important treatment for anthracycline- and taxane-resistant metastatic breast cancer(MBC), especially for triple-negative breast cancer(TNBC). Here, we presented the results of a phase IV clinical study of the third-generation platinum compound lobaplatin (LBP) in the treatment of MBC. Methods: Patients(Pts) diagnosed with MBC who had previously rec...

New potential therapeutic-sequence strategies of TDM1 in the revolutionary era of metastatic HER2-positive breast cancer treatment: a monocentric retrospective experience.
https://meetinglibrary.asco.org/record/188498
Maria Vita Sanò

May 28th, 2020 - Background: EMILIA study showed benefits in terms of both progression free survival (PFS) and overall survival (OS) administering Ado-trastuzumab emtansine (T-DM1) vs lapatinib-capecitabine in HER2+ mBC patients (pts) treated at least with a previous trastuzumab-taxane-based therapy. However a paucity of data is available on TDM1 efficacy after dual anti HER2 blockade with pertuzumab and trastu...

Del-1 and MFG-E8 expression to differentially modulate prognosis of patients with triple-negative breast cancer.
https://meetinglibrary.asco.org/record/188754
Soo Jung Lee, MD. Ph.D.

May 28th, 2020 - Background: Del-1 was previously found to be prognostic biomarker in early breast cancer patients. Del-1 shares both structural and functional homology with Milk fat globule-epidermal growth factor-factor VIII (MFG-E8). To date, the biological functions of Del-1 and MFG-E8 have not been sufficiently compared in side-by-side experiments. MFG-E8 is a secreted glycoprotein from macrophages that pr...

Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2- advanced breast cancer.
https://meetinglibrary.asco.org/record/188757
Jesús Fuentes Antrás

May 28th, 2020 - Background: Combination therapeutic strategies including CDK4/6 inhibitors and an endocrine backbone are the standard of care of treatment for patients with estrogen receptor positive (ER+)/HER2- advanced breast cancer (ABC). Endocrine agents mainly include aromatase inhibitors, which target ER-driven transcription, and fulvestrant, which functions as ER antagonist. PI3K-AKT-mTOR is a key point...

Metastasis by semi-quantitative oestrogen receptor expression in stage I-III early diagnosed triple positive breast cancer patients.
https://meetinglibrary.asco.org/record/188848
Jasmine Van de Kerkhof

May 28th, 2020 - Background: Some breast cancer subtype-specific demographics and histopathological characteristics can be associated with metastatic outcome. Semi-quantitative oestrogen receptor (sqER) is prognostic in ER-positive HER2-negative tumours. Here, we studied sqER for outcome in early diagnosed triple positive breast cancers (TPBC;ER+/PR+/HER2+). Methods: Retrospective monocentric study of all conse...

Expression of CD44 and CD133 markers in regional metastases from breast cancer.
https://meetinglibrary.asco.org/record/188844
Aleksandr B. Sagakyants

May 28th, 2020 - Background: High incidence and mortality of breast cancer (BC) require a constant search for the most informative and effective methods of diagnosis and treatment evaluation. The purpose of the study was to analyze phenotypic characteristics of cancer stem cells in tumor tissues and regional metastases of breast cancer (BC). Methods: The study included 20 BC patients with regional metastases (l...

Assessment for markers of poor prognosis in a real-world evidence study of treatment patterns in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea and Taiwan.
https://meetinglibrary.asco.org/record/188588
Diego Novick, MD, PhD

May 28th, 2020 - Background: To assess how patient characteristics impact treatment patterns and real-world effectiveness among patients with hormone receptor (HR+)/human epidermal growth receptor 2-negative (HER2-) locally advanced and metastatic breast cancer (ABC) in Korea and Taiwan. Methods: We conducted a retrospective chart review comprising 227 female patients aged ≥ 18 years and diagnosed HR+/HER2- ABC...

Economic evaluation of SP142 IHC assay versus 22C3 IHC assay in patients with unresectable locally advanced or metastatic triple-negative breast cancer in the Brazilian private healthcare system.
https://meetinglibrary.asco.org/record/188751
Rodrigo Shimabukuro Ho

May 28th, 2020 - Background: The IMpassion130 trial has demonstrated that atezolizumab plus nab-paclitaxel results in significant clinical benefits for patients with unresectable locally advanced or metastatic (aTNBC). The SP142 IHC assay is a clinically validated and FDA-approved PD-L1 test to identify patients with aTNBC for treatment with atezolizumab plus nab-paclitaxel. A post hoc analysis of IMpassion130 ...

Feasibility of real-time serial comprehensive tumor analytics: Pilot study of olaparib and durvalumab in metastatic triple negative breast cancer (mTNBC).
https://meetinglibrary.asco.org/record/188745
Allen Li, MD, MS

May 28th, 2020 - Background: Longitudinal analysis of serial tumor biopsies is an under-utilized approach to studying adaptive mechanisms of resistance. We have established a comprehensive analytic platform to evaluate real-time trial sample analysis to inform precision oncology combinations in mTNBC. The primary endpoint of the study is feasibility of completing all CLIA assays within 28 days of biopsy. Method...

Can tumor cells be distinguished from blood cells by mechanical parameters? A label-free CTC detection approach.
https://meetinglibrary.asco.org/record/189199
Ivonne Nel

May 28th, 2020 - Background: Even years after successful treatment of the primary tumor about 30% of breast cancer patients are suffering from metastatic relapse. One reason might be hematogenous spread. Therefore circulating tumor cells (CTC) in the blood might be interesting and easy accessible surrogate markers for disease monitoring. Due to phenotypical, mechanical and functional changes during cancer progr...

Keeping oncologists current with CDK4/6 inhibitors in HR+ breast cancer: The impact of online education.
https://meetinglibrary.asco.org/record/188636
Kinjal Parikh, PharmD, BCOP

May 28th, 2020 - Background: CDK4/6 inhibitors have revolutionized the care of patients with hormone receptor positive (HR+), HER2-negative breast cancer, improving survival outcomes. There are multiple CDK4/6 inhibitors available that differ in their pharmacologic features, reported outcomes, therapeutic indications, and adverse event profiles. Education is needed to empower clinicians to optimally use these a...

Application of MammaPrint test on Chinese patient with breast cancer.
https://meetinglibrary.asco.org/record/189596
Chen Tian

May 28th, 2020 - Background: A 70-gene prognosis-signature, known as MammaPrint (MP), is validated as a good predictor of recurrence in patients with ER+/HER2- early stage breast cancer in Europe and America. Previous studies on Japanese and Korean breast cancer patients showed that the proportion of MP Low-Risk tumours is significantly lower than the percentage which reported in previous studies. Here we use M...

Factors associated with low chemotherapy dosing in high risk breast cancer.
https://meetinglibrary.asco.org/record/188917
Leilani Hernandez

May 28th, 2020 - Background: Chemotherapy dose is often reduced or delayed due to adverse effects. However, a low relative dose intensity (RDI) is associated with reduced disease control and survival. There is little data among patients receiving modern breast cancer regimens regarding the risk of low RDI, or factors associated with it. Methods: We used an institutional registry at a large multidisciplinary can...

The next generation of cerebrospinal fluid (CSF)-based molecular diagnostics: Improving sensitivity and actionability in breast and lung cancer patients with CNS involvement.
https://meetinglibrary.asco.org/record/189889
Veena M. Singh, MD

May 28th, 2020 - Background: Liquid biopsy has emerged as a minimally invasive and cost-effective strategy to assess cancer biomarkers without the risk of complications associated with surgical biopsies. Once a tumor has metastasized to the brain, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) can be found in the cerebrospinal fluid (CSF). We analyzed CSF samples from patients(pts) with primar...

Development of an artificial intelligence model to dynamically predict metastatic recurrence of early-stage breast cancer patients.
https://meetinglibrary.asco.org/record/189143
Vivek Prabhakar Vaidya

May 28th, 2020 - Background: Models that can dynamically predict risk of metastatic breast cancer (MBC) recurrence based on cumulative historical clinical data could help guide patient care & surveillance decisions. The objectives of this study were to predict risk of MBC recurrence dynamically from any point after 1 year of initial diagnosis in a BC patient’s journey. We show representative results for predict...